Get started

Canslim

CDW CORP (CDW) We are testing the William O´neils CANSLIM METHOD. We have tested some stocks sugetions Found in the MARKETSMITH stock suscription. Test have been made with small amounts. This Is one of the best performing stocks of 2019. we are expecting it to be on the top market leaders. EPS RATING 99 Group RS A RS RATING A C.R, 99 RS 95 this stock has made a strong flat base rectangular pattern from 162 to 179.. I will set up a stop buying order at a price of 180.66 wating for a price break.
NASDAQ:CDWLong
by fonsecadr
MICRO FOCUS INTERNATIONAL PLC SPON ADRWe are testing the William O´neils CANSLIM METHOD. We have tested some stocks sugetions Found in the MARKETSMITH stock suscription. Test have been made with small amounts. This Is one of the best performing stocks of 2019. we are expecting it to be on the top market leaders. EPS RATING 99 Group RS A RS RATING A C.R, 99 RS 95 this stock has made a strong flat CUP AND A HANDLE from 22 to 27.. I will set up a stop buying order at a price of 180.66 wating for a price break.
MLong
by fonsecadr
1
Arrowhead Pharmaceuticals Massive Institutional AccumulationStock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies. Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future. Late 2016 -Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program -Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target -Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments up to $617 million in option payments, and development, regulatory and sales milestone payments "Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy." "We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
NASDAQ:ARWRLong
by alipipefitter
My first stock chart technical analysisI've recently been diving into the stock market world and the realm of technical analysis. I started reading a book written by William O'Neil called "How To Make Money in Stocks". To keep this short, he discusses a chart pattern called the Cup with Handle. So after reading about this a bit I decided to go out and find one on my own. Well I think I found one right here in a brand that I personally like, $AMD. I'd definitely appreciate feedback from more experienced and professional technical analysis traders. I've only just begun this journey and I'm excited to see what I can learn and what I'll be able to accomplish once I actually start trading with real $$. Edit: The 2 text boxes in the bottom window pointing to volume action are incredibly small and I have no idea how to fix that. The Top box says "~200% Volume spike at pivot point" and the other "Noticeable volume dry up in price pullback"
NASDAQ:AMD
by staheli.andrew.g
2
CLASSIC CANSLIM STOCKI learned about canslim from a guy i know online named Mike Rich, everything I know is because of him. Positive earnings growth in the 20's and 30 percentile over previous quarter, cup and handle, and double bottom, positive cash flow and proven profits with a growing and revolutionary business model. Too many shares to not take profits. Sell 1/2 at $203, buy back if DOW and NASDAQ are still relatively healthy, on next earning report of 20% 30% increase over previous quarter. Sell whole position if it starts acting up because i don't trust the 1 BILLION shares. Plus I believe in OMENS, and the name ALIBABA has a bad ring ;)
NYSE:BABALong
by alipipefitter